Format

Send to

Choose Destination
Lancet Oncol. 2007 Oct;8(10):933-9.

Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.

Author information

1
Department of Medicine, and UCSF Comprehensive Cancer Center, University of California-San Francisco, 94143, USA. andrew.hsieh@ucsf.edu

Abstract

Many attempts have been made to derive genetic signatures for progressive prostate cancer for both prognostic and therapeutic purposes. These investigations have resulted in the discovery of many pathways, but the signatures exhibit heterogeneity and restricted reproducibility. A thorough and disciplined analysis of genes with androgen-response elements that are expressed in progressive, castration-resistant prostate cancer is an integral step towards the development of new therapeutic or diagnostic targets. We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets.

PMID:
17913662
DOI:
10.1016/S1470-2045(07)70316-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center